Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5290]

Therapeutic potential of a novel mixture of mRNA in nanoparticles overcomes tumour progression

Therapeutic potential of a novel mixture of mRNA in nanoparticles overcomes tumour progression

Experts warn cervical cancer will not be eliminated unless expertise of advocacy groups and the needs of women are reflected in screening strategies

Experts warn cervical cancer will not be eliminated unless expertise of advocacy groups and the needs of women are...

Unexpected discovery revives abandoned breast cancer treatment

Unexpected discovery revives abandoned breast cancer treatment

B7-H4 as a therapeutic target in adenoid cystic carcinoma

B7-H4 as a therapeutic target in adenoid cystic carcinoma

DNA secreted by tumour cell extracellular vesicles prompts anti-metastatic immune response

DNA secreted by tumour cell extracellular vesicles prompts anti-metastatic immune response

European Commission approves tislelizumab for first-line treatment of advanced/metastatic oesophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer

European Commission approves tislelizumab for first-line treatment of advanced/metastatic oesophageal squamous...

Study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

Study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and...

Scientists can predict how long prostate cancer patients will respond to olaparib

Scientists can predict how long prostate cancer patients will respond to olaparib

IND clearance from FDA for ISM5939, an oral ENPP1 inhibitor treating solid tumours

IND clearance from FDA for ISM5939, an oral ENPP1 inhibitor treating solid tumours

More from ecancer